Not an accelerator! We build with you.
IKP ARK embeds operators into your startup to turn deep science into a fundable, Series A–ready company.
Yura is building a gel-free textile ECG wearable that delivers closed-loop heart rate variability (HRV) biofeedback through gentle haptic cues. Its patented electrode technology comes out of CeNSE at IISc and captures true ECG rather than optical estimates. This brings clinical-grade biofeedback out of the clinic and into everyday life.
Lifespark builds neurotech for people living with Parkinson's. Its CDSCO-approved wearable, WALK, uses neural stimulation to help with freezing of gait, and it is backed by a sham-controlled clinical trial. PATHFINDER, its companion platform, brings gamified home rehab with remote clinician monitoring.
B Cell Biologics is developing ElectroSense AI, a portable point-of-care reader with swappable disease cartridges, starting with HPV screening for cervical cancer and cardiac troponin. Built on in-house antibodies and a patented magnetic-flow design, it aims to replace multi-day lab send-outs with fast, low-cost testing where patients are.
Renu MedTech is building InsuPatch, a lightweight tubeless insulin patch pump designed for India. At a fraction of the cost of existing pumps, with low monthly consumables, InsuPatch aims to make modern insulin delivery accessible to the millions of people living with Type 1 diabetes.
Spartis uses AI to turn two routine X-rays into a 3D bone-density map. This enables osteoporosis screening without a DEXA or CT scan, and with no extra hardware. Delivered through a simple web app, it helps clinicians catch bone loss early, before a fracture happens.
IKP ARK is a venture a program for deep-science startups in MedTech and HealthTech - taking you from working proof-of-conept to a monetisable, fundable company through embedded operators and disciplined execution. This is not an incubator, grant program, or pitch platform. ARK is a structured, time-bound system where operators are accountable alongside founders—built on evidence, not opinions, and execution, not promises.
A co-building partnership where IKP’s operator team (Black Belts) is embedded inside your venture—retiring every commercial risk from productization to regulatory to fundraising.
Imminent industry leaders, rigorous academics, and seasoned deep-tech entrepreneurs — handpicked by IKP leadership for each venture's specific domain and phase. The right people, for the right problem, at the right time.
A dedicated team of operators, domain experts, and leaders committed to your venture's success.
Structured as a 12-month, 3-phase program. IKP equity is milestone-vested - earned through capital, execution, and co-building.
IKP leads structured diagnostic interviews across all 7 stack elements — every gap named, every risk scored (Days 1–2). Then roadmap building domain by domain, led by IKP’s embedded specialists (Days 3–5). Day 6 is Blueprint Day: both parties sign the Venture Blueprint and commit to Phase 2 — or part ways cleanly.
The most intensive sustained phase. Every stack element attacked in focused micro-sprints until the risk is retired. Weekly PMU/Operations team sessions — milestone scorecard, blockers, commitments, IKP action items.
Founders lead. IKP shifts to a strategic embedded partner with capital at stake—aligned for outcomes. IKP opens up manufacturing, regulatory, and clinical infrastructure. Post 12 months, IKP has the option to invest further.
Up to ₹ 1 Cr per startup, deployed milestone by milestone. Not a blanket cheque — capital earned against defined progress.
Embedded in your venture. CDSCO, FSSAI, biosafety, clinical validation strategy.
Shreyas Kuduva embedded sprint-by-sprint. DFM review, supply chain mapping, vendor qualification.
GTM hypothesis, fundraising narrative, business model — all stress-tested by the PMU team.
IKP’s 20+ year network of research institutions, clinical partners, industry collaborators, and investors
SmartFab infrastructure access, IP/legal/finance support, and best-in-class mentors.
"Deep science fails not because of weak science. It fails because the path from lab to market is fragmented and poorly supported" — THE IKP ARK THESIS
If your science is ready and you're committed to building a company — not continuing research.
Contact Aaqib Jameel (Programme Lead) directly — we respond to every serious inquiry.
Formal open call published following the April 2026 launch event via IKP's website.